Select Page

XOLAIR (omalizumab) for injection, for subcutaneous use. Initial U.S. Approval: 2003

XOLAIR (omalizumab) for injection, for subcutaneous use. Initial U.S. Approval: 2003

XOLAIR is a prescription medicine. XOLAIR is used to treat moderate to severe persistent asthma treatment.
INDICATIONS AND USAGE
Xolair is an anti-IgE antibody indicated for:
• Moderate to severe persistent asthma in patients 6 years of age and older with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms that are inadequately controlled with inhaled
corticosteroids
• Chronic idiopathic urticaria in adults and adolescents 12 years of age and older who remain symptomatic despite H1 antihistamine treatment
DOSAGE FORMS & STRENGTHS
For injection: Lyophilized, sterile powder in a single-use 5mL vial, 150 mg.
Manufactured By: Genentech
Prescribing Information URL: Click Here

Procedure to buy XOLAIR ® (omalizumab) for injection?
To buy XOLAIR ® (omalizumab) for injection, patients can simply fill the order form or can send mail at info@bioniquehealthcare.com. or can also send Whatsapp message at +91 96677 50889. You will get reply within few hours with pricing and procedure details. Note:- the order will be confirmed only after the receipt of valid prescription of doctor.

Category:

Omalizumab, sold under the brand name Xolair, is a medication originally designed to reduce sensitivity to allergens. It has been used to try to control severe allergic asthma, which does not respond to high doses of corticosteroids and less widely for chronic spontaneous urticaria.

Allergic asthma
Omalizumab is used to treat people with severe, persistent allergic asthma, uncontrollable with oral or injectable corticosteroids. Those patients have already failed step I to step IV treatments and are in step V of treatment. Such a treatment scheme is consistent with the widely adopted guidelines for the management and prevention of asthma, issued by Global Initiative of Asthma (GINA), which was a medical guidelines organization launched in 1993 in collaboration with the National Heart, Lung, and Blood Institute, National Institutes of Health, USA, and the World Health Organization.

Chronic spontaneous urticaria
Omalizumab is indicated for chronic spontaneous urticaria in adults and adolescents (>12 years old) poorly responsive to H1-antihistamine therapy. When administered subcutaneously once every four weeks, omalizumab has been shown to significantly decrease itch severity and hive count.

Documentation

  1. Doctor’s Prescription – We would require prescription from registered medical practitioner stating product name, dosage, duration of treatment and diagnosis.
  2. Patient’s Medical history – We would require all test reports and medical reports of the patient for last 3 months.
  3. Patient’s Identity card – We will require scan copy of patient’s identity card and proof of residence to initiate documentation process. you can use copy of passport, driving license, employee ID card or any photo id document as your identity card.

For Overseas Patient

Can I get anti-cancer medicines even if I am not based in India?

Almost all countries across the world have provisions for granting access to drugs prior to marketing approval for personal use for patients who have exhausted all other treatment options available in their country. The Bionique Healthcare can help patients in accessing/importing Ant-cancer medicines, unapproved in their home country against a legitimate prescription and in conformity with all local laws and regulations of their home country.

Send your query to find the best price of –

XOLAIR ® (omalizumab) for injectionn in South East Asia – China (Beijing, Chongqing, Shanghai, Tianjin and Shenzhen), Cambodia, Indonesia, Malaysia, the Philippines, Singapore, Thailand, Vietnam, Hong Kong.
XOLAIR ® (omalizumab) for injectionn in United Arab Emirates – Iraq, Iran, Saudi Arabia, Jordan.
XOLAIR ® (omalizumab) for injectionn in North America – Mexico.
XOLAIR ® (omalizumab) for injectionn in South America – Argentina, Brazil, Chile, Colombia, Peru, Venezuela.
XOLAIR ® (omalizumab) for injectionn in Europe – Romania, Switzerland, Georgia, Turkey, Italy, UK, Ukraine, Azerbaijan, Latvia, Poland, Slovakia.
XOLAIR ® (omalizumab) for injectionn in Russia CIS – Armenia, Kazakhstan, Moldova, Tajikistan, Turkmenistan, Uzbekistan, Mongolia.
XOLAIR ® (omalizumab) for injectionn in African Countries – Algeria, Mauritius, Uganda, Zimbabwe.
XOLAIR ® (omalizumab) for injectionn in Australia and New Zealand.

For Indian Patient

Ani-Cancer XOLAIR ® (omalizumab) for injectionn are prescription drug. 

We facilitate by-

  • Helping in documentation to import the medicine for personal use.
  • Finding Genuine and reliable source in USA, Europe and Japan.
  • Ensuring 100% transparency.

XOLAIR ® (omalizumab) for injectionn can be shipped to Ahmedabad, Bangalore, Chennai, Cochin, Hyderabad, Delhi, Haryana, Jaipur, Jammu and Kashmir, Himachal Pradesh, Kolkata, Lucknow, Mumbai, Pune, Punjab and other cities in India. Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. 

Reviews

There are no reviews yet.

Be the first to review “XOLAIR (omalizumab) for injection, for subcutaneous use. Initial U.S. Approval: 2003”

Your email address will not be published. Required fields are marked *

Anti-Cancer Medicine Supplier.

Bionique Healthcare is a consulting pharmaceutical company which assist Patients in accessing medicines in India. Bionique Healthcare facilitates such access only against valid prescriptions in conformity with all local laws and regulations.

Patients/ Clinicians / Researchers can contact Bionique at +91 9667750889 or write to at – info@bioniquehealthcare.com.

Product Disclaimer

Bionique Healthcare does not manufacture, supply, re-sell or retail any drugs or medicines. All trademarks and other intellectual property in relation to drugs and medicines supplied to you by suppliers are owned by their respective manufacturer or licensee. 

Bionique Healthcare does not lay any claim on them.